Ladenburg upgraded Acrivon Therapeutics to Buy from Neutral with a $16 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Acrivon reports data from ongoing ACR-368 registrational intent Phase 2 study
- Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
- Acrivon Therapeutics to host investor event on Phase 2 data of ACR-368
- Acrivon Therapeutics price target lowered to $18 from $21 at Oppenheimer
- Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights